An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

February 29, 2012

Conditions
Carcinoma, Non-Small-Cell LungHead and Neck Neoplasms
Interventions
OTHER

[18F]-ML-10 in conjunction with PET imaging

Subjects will receive two to three intravenous (IV) doses of \[18F\]-ML-10. The dose for each \[18F\]-ML-10 dose will be 5.50 MBq/Kg or 0.15 mCi/Kg but will not exceed 500.00 MBq (13.50 mCi) per administration.

Trial Locations (4)

10029

RECRUITING

Mount Sinai, New York

15232

RECRUITING

University of Pittsburgh, Pittsburgh

Unknown

RECRUITING

BWH, Boston

07666

RECRUITING

Holy Name Medical Center, Teaneck

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Aposense Ltd.

INDUSTRY

NCT01260480 - An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation | Biotech Hunter | Biotech Hunter